REGENXBIO Files 2025 Annual Report
Ticker: RGNX · Form: ARS · Filed: Apr 14, 2026
Sentiment: neutral
Topics: annual-report, sec-filing, biotech
TL;DR
REGENXBIO dropped its 2025 ARS. Check financials.
AI Summary
REGENXBIO Inc. filed its Annual Report to Security Holders (ARS) on April 14, 2026, for the period ending December 31, 2025. The company, located at 9804 Medical Center Drive, Rockville, MD 20850, operates in the Biological Products sector. The filing details its performance and activities for the fiscal year 2025.
Why It Matters
This filing provides shareholders and potential investors with a comprehensive overview of REGENXBIO's financial health and operational progress during 2025, crucial for investment decisions.
Risk Assessment
Risk Level: low — This is a routine annual filing and does not contain new material events or significant financial changes that would indicate elevated risk.
Key Players & Entities
- REGENXBIO Inc. (company) — Filer of the ARS
- 2026-04-14 (date) — Filing Date
- 2025-12-31 (date) — Period of Report
- 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 (address) — Mailing and Business Address
FAQ
What is the CIK number for REGENXBIO Inc.?
The CIK number for REGENXBIO Inc. is 0001590877.
When was the ARS filing accepted by the SEC?
The ARS filing was accepted on 2026-04-14 at 17:15:04.
What is the fiscal year end for REGENXBIO Inc.?
The fiscal year end for REGENXBIO Inc. is 1231.
What is the SIC code for REGENXBIO Inc.?
The SIC code for REGENXBIO Inc. is 2836, which pertains to Biological Products, (No Diagnostic Substances).
What is the file number associated with this filing?
The file number associated with this filing is 001-37553.
Filing Details
This Form ARS (Form ARS) was filed with the SEC on April 14, 2026 regarding REGENXBIO Inc. (RGNX).